Protalix BioTherapeutics, Inc. (PLX) Form 8-K — May 13, 2026
Protalix BioTherapeutics, Inc. reported a net income of $18.3 million for the first quarter of 2026, a significant improvement from the net loss of $3.6 million in the same period last year. This was primarily driven by a $25 million milestone payment received from Chiesi Farmaceutici S.p.A. following the European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio.
Key figures
- Eps
- 0.23
- Revenue
- 33750
- Net Income
- 18317
- Total Debt
- 0
- Cash Position
- 51100
- Milestone payment
- 25000
Price after filing
1 day: +3.6%7 days: +4.1%30 days: +6.2%
Close on the filing date to close N calendar days later (from $1.93). Historical, not a forecast.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.